Literature DB >> 3741541

Possible role of platelet activating factor (PAF) in disseminated intravascular coagulation (DIC), evidenced by use of a PAF antagonist, CV-3988.

Y Imura, Z Terashita, K Nishikawa.   

Abstract

The i.v. infusion of endotoxin (ET) (0.25 mg/kg/hr for 4 hr) induced disseminated intravascular coagulation (DIC) in rats; thrombocytopenia, prolongation of prothrombin time (PT) and partial thromboplastin time (PTT), hypofibrinogenemia and elevated levels of fibrinogen/fibrin degradation products (FDP) were observed. Platelet activating factor (PAF) (8 micrograms/kg/hr for 4 hr) also induced DIC-like changes, except in platelets. A specific PAF antagonist, CV-3988 (2 mg/kg bolus 5 min before ET + 1 or 2 mg/kg/hr for 4 hr of ET infusion) improved all the parameters that had been altered by both ET and PAF. CV-3988 (2 mg/kg bolus 2 hr after ET + 2 mg/kg/hr for 2 hr of ET infusion) also had beneficial effects on DIC. CV-3988 itself had no effects on the parameters of DIC. These results strongly suggest that PAF may play a role in the pathogenesis of DIC and CV-3988 may prove to be useful for the treatment of DIC.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3741541     DOI: 10.1016/0024-3205(86)90444-3

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  9 in total

1.  Effect of a selective PAF antagonist SM-10661 ((+/-)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one HCl) on experimental disseminated intravascular coagulation (DIC).

Authors:  N Imanishi; Y Komuro; S Morooka
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

2.  Effectiveness and tolerability of CV-3988, a selective PAF antagonist, after intravenous administration to man.

Authors:  J Arnout; A van Hecken; I De Lepeleire; Y Miyamoto; I Holmes; P De Schepper; J Vermylen
Journal:  Br J Clin Pharmacol       Date:  1988-04       Impact factor: 4.335

3.  Occurrence of disseminated intravascular coagulation (DIC) in active systemic anaphylaxis: role of platelet-activating factor.

Authors:  I H Choi; T Y Ha; D G Lee; J S Park; J H Lee; Y M Park; H K Lee
Journal:  Clin Exp Immunol       Date:  1995-06       Impact factor: 4.330

4.  Effects of UR-12633, a new antagonist of platelet-activating factor, in rodent models of endotoxic shock.

Authors:  M Giral; D Balsa; R Ferrando; M Merlos; J Garcia-Rafanell; J Forn
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

5.  Clinical and experimental studies on the role of platelet-activating factor (PAF) in the pathogenesis of septic DIC.

Authors:  S Ono; S Tamakuma; H Mochizuki; M Kinoshita; Y Ohkusa; S Aosasa; Y Oda; H Ohe
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

Review 6.  The contribution of platelets to intravascular arrest, extravasation, and outgrowth of disseminated tumor cells.

Authors:  Amelia Foss; Leonel Muñoz-Sagredo; Jonathan Sleeman; Wilko Thiele
Journal:  Clin Exp Metastasis       Date:  2019-11-22       Impact factor: 5.150

7.  The platelet activating factor as a pivotal mediator of shock after liver ischemia.

Authors:  T Fukuoka; Y Nakajima; H Nakano
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

Review 8.  The most important biomarker associated with coagulation and inflammation among COVID-19 patients.

Authors:  Ling-Zhi Hong; Zhang-Xuan Shou; De-Ming Zheng; Xue Jin
Journal:  Mol Cell Biochem       Date:  2021-03-19       Impact factor: 3.842

Review 9.  Factor XII-Driven Inflammatory Reactions with Implications for Anaphylaxis.

Authors:  Lysann Bender; Henri Weidmann; Stefan Rose-John; Thomas Renné; Andy T Long
Journal:  Front Immunol       Date:  2017-09-15       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.